Skip to main
AUTL
AUTL logo

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is advancing its clinical-stage pipeline of next-generation programmed T-cell therapies, with a heightened focus on achieving substantial improvements in manufacturing processes that could lead to gross margins of 60-70% over time. The strong efficacy and safety data from pivotal studies, particularly regarding Aucazyl's performance, suggest that the drug may significantly outperform existing treatments, potentially establishing itself as the preferred CAR-T therapy in specific market segments. Furthermore, observed lower exhaustion markers correlated with improved patient outcomes, reinforcing the potential of Autolus's therapeutic innovations in enhancing treatment effectiveness in oncology.

Bears say

Autolus Therapeutics faces a challenging outlook as projected sales for 3Q:25 are expected to remain flat quarter-over-quarter due to recent changes in CMS reimbursement policies, with a potential recovery not anticipated until 4Q:25. Additionally, production capabilities for CAR-T therapeutics may not meet expectations, indicating potential shortfalls in revenue generation. The presence of adverse events such as cytokine release syndrome and neurotoxicity raises concerns about the broader applicability and market acceptance of Autolus's therapies, further contributing to the negative financial sentiment surrounding the company's stock.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.